We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Syncona Limited (SYNC) Ordinary NPV

Sell:122.40p Buy:123.80p 0 Change: 2.60p (2.15%)
FTSE 250:0.27%
Market closed Prices as at close on 26 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:122.40p
Buy:123.80p
Change: 2.60p (2.15%)
Market closed Prices as at close on 26 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:122.40p
Buy:123.80p
Change: 2.60p (2.15%)
Market closed Prices as at close on 26 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

News, reports & tips

  • Syncona NAV grows in Q3

    8 February 2024 09:04

    (Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its...

  • Syncona net asset value falls, co-founder steps down

    16 November 2023 08:44

    (Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2%...

  • Syncona shares slump as Novartis ends eye treatment development

    11 September 2023 15:42

    (Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of...

  • Syncona reports slight dip in net assets

    10 August 2023 08:34

    (Sharecast News) - Healthcare investor Syncona reported a slight dip in net assets in its quarterly update on Thursday, to £1.24bn, down from £1.26bn at the end of March.

  • Syncona annual NAV falls in tough macro conditions

    15 June 2023 07:39

    (Sharecast News) - Health investor Syncona reported a fall in annual net asset value, driven by falls in its listed holdings and the partial write-down of neurological gene therapy company SwanBio, partially...

  • Syncona launches retinal disease-focussed Beacon Therapeutics

    12 June 2023 07:51

    (Sharecast News) - Healthcare company developer and investor Syncona announced the launch of Beacon Therapeutics on Monday.

  • Syncona said direct exposure to SVB 'de minimis'

    13 March 2023 07:55

    (Sharecast News) - Life sciences investor Syncona said it had a minimal exposure to the collapsed Silicon Valley Bank.

  • Syncona NAV falls in Q3

    7 February 2023 07:16

    (Sharecast News) - Healthcare company Syncona said on Tuesday that net assets had fallen in the three months ended 31 December, principally due to the declining value of its quoted holdings and foreign...

  • Syncona investee Autolus sells more American shares

    22 December 2022 08:04

    (Sharecast News) - Life science-focussed healthcare company Syncona said on Thursday that its portfolio company Autolus Therapeutics had announced that the underwriters of its public offering of American...

  • Syncona's Autolus leukemia treatment meets trial endpoint

    9 December 2022 07:21

    (Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.

  • Syncona makes 'positive' operational and clinical progress in H1

    17 November 2022 08:16

    (Sharecast News) - Healthcare company Syncona said on Thursday that it had delivered "positive operational and clinical progress" across its portfolio against a challenging macro backdrop in the...

  • Syncona to buy US biotech AGTC for $23.5m

    24 October 2022 07:42

    (Sharecast News) - Healthcare group Syncona said on Monday that it has agreed to buy US biotechnology firm Applied Genetic Technologies Corporation (AGTC) for around $23.5m, or $0.34 per share, in cash.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2024. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.